Skip to search formSkip to main contentSkip to account menu

palosuran

Known as: 1-(2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl)-3-(2-methylquinolin-4-yl)urea sulfate salt 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Urotensin receptor antagonist palosuran attenuates cyclosporine-a-induced nephrotoxicity in rats.
BACKGROUND Cyclosporine-A (CsA) is widely used for immunosuppressive therapy in renal transplantation. Nephrotoxicity is the main… 
2015
2015
Palosuran: clinical pharmacology of a urotensin-II receptor antagonist in Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus (Type 2 DM) is a growing global public health threat, leading to a significant cost burden to society… 
2014
2014
Palosuran Treatment Effective as Bosentan in the Treatment Model of Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a progressive and fatal disorder that any valuable advance in the management of diseases… 
2013
2013
THU0487 Palosuran Treatment, Effective as Bosentan in the Treatment of Pulmonary Arterial Hypertension (PAH) Model
Objectives Due to its high morbidity and mortality rates, pulmonary arterial hypertension is a life threatening and a progressive… 
2012
2012
Effectiveness of Palosuran in Bleomycin-Induced Experimental Scleroderma
Systemic sclerosis (SSc) is a disease characterized by skin and internal organ involvement. There is progressive accumulation of… 
2011
2011
Development of filtration-based time-resolved fluorescence assay for the high-throughput screening of urotensin II receptor antagonist.
The time-resolved fluorescence (TRF) receptor binding assay has many advantages over the traditional radioligand binding assay in… 
2011
2011
Urotensin II in the Pathogenesis of Atherosclerosis in Cholesterol Fed Rats
Background: Atherosclerosis is the most common cause of ischemic heart diseases. Urotensin II is the most potent vasoactive… 
2010
2010
Urotensin-II Contributes to Pulmonary Vasoconstriction in a Perinatal Model of Persistent Pulmonary Hypertension of the Newborn Secondary to Meconium Aspiration Syndrome
Meconium aspiration syndrome (MAS) disrupts perinatal decreases in pulmonary vascular resistance (PVR) and is the commonest cause… 
2010
2010
Expression of Urotensin II and Its Receptor in Human Liver Cirrhosis and Fulminant Hepatic Failure
ObjectivesUrotensin II [U-II] plasma levels are increased in liver cirrhosis [LC] and are discussed as an important mediator of… 
2009
2009
Pharmacokinetics and Pharmacodynamics of the Urotensin‐II Receptor Antagonist Palosuran in Healthy Male Subjects
Palosuran is a new potent and specific antagonist of the human urotensin II (U‐II) receptor (UT receptor). This entry‐into‐humans… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)